A journey of ten thousand miles begins with a single step!

On July 24, 2023, we learned from the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration that our blockbuster product Memantine Hydrochloride was successfully transferred to A!

Memantine hydrochloride

As the only non-competitive NMDA receptor antagonist in clinic, memantine hydrochloride can inhibit the excessive activation of NMDA receptor to reduce excitotoxicity and protect neurons, while not affecting the physiological activation of NMDA receptor needed for cognition. It is an important drug for treating moderate to severe Alzheimer's disease.

Basic information

Memantine Hydrochloride English name: Memantine Hydrochloride Chemical name: 1-amino-3,5-dimethyladamantaneamine hydrochloride CAS No.: 41100 -52-1 Molecular formula: C12H21 N.HCl Molecular weight: 215.76, Appearance: White crystal or powder. Melting range: 290 ℃ ~ 295 ℃ Approved dosage form: tablet, oral solution, sustained-release capsule.

Project progress

The API has been successfully approved for marketing, with the registration number of "Y20200001003" and the registration status of "A".